Merck booked just under $600 million last year in alliance revenues from the pair, but its attention is now moving to new therapies including sotatercept, a TGF-beta-targeting PAH drug Merck ...

To sign up for Becker's Payer Issues E-Newsletter or any of our other E-Newsletters, click here. If you are experiencing difficulty receiving our newsletters, you may ...